Karyopharm Therapeutics, Inc. is a pharmaceutical company based in the United States that focuses on developing innovative cancer treatments targeting nuclear export. Their approved drug, XPOVIO (selinexor), is used to treat various hematologic malignancies. With a medium risk rating score of 24.4, Karyopharm Therapeutics, Inc. is dedicated to discovering and commercializing drugs for cancer and other diseases. The company generates its revenue primarily from the United States.